UBS Group
OTLKW

UBS Group’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

UBS Group’s Portfolio OTLKW Stock Details OTLKW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-849
Closed – – 10589
2021
Q2 		$0 Buy
+849
New +$416 ﹤0.01% 10201

Other funds holding OTLKW

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group's OTLKW Position: Q3 2021 in Review

UBS Group sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q3 2021, closing a stake of 849 shares.

UBS Group first reported a position in OTLKW in Q2 2021 and held it in 1 quarter. The position peaked at $0 in Q2 2021. 4 funds tracked by Wall St. Rank hold OTLKW as of Q3 2021.

  • UBS Group reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q3 2021 after selling out during the quarter.
  • UBS Group sold 849 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q3 2021.
  • UBS Group first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q2 2021 and held it in 1 quarter.
  • UBS Group's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $0 in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q3 2021.

Based on UBS Group's 13F filing for Q3 2021, filed 15 Nov 2021.